Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG

Author:

Moreau Alexandre1,Lacroix-Desmazes Sébastien1,Stieltjes Natalie1,Saenko Evgueni1,Kaveri Srini V.1,D'Oiron Roseline1,Sultan Yvette1,Scandella Dorothea1,Kazatchkine Michel D.1

Affiliation:

1. From INSERM U 430 and Université Pierre et Marie Curie, Hôpital Broussais, Paris, France; Centre des Hémophiles, Hôpital Cochin, Paris, France; Holland Laboratory, American Red Cross, Rockville, MD; and Centre de Traitement des hémophiles, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Abstract

We have analyzed the properties of anti-factor VIII (FVIII) immunoglobulin (Ig) G recovered by affinity chromatography on FVIII-Sepharose from the IgG fraction of the plasma of healthy individuals and nonresponder patients with hemophilia A. Affinity-purified anti-FVIII antibodies were found to neutralize FVIII activity and to bind to FVIII with an affinity similar to that of anti-FVIII IgG that had been affinity-purified from the plasma of inhibitor-positive hemophilia patients and of patients with anti-FVIII autoimmune disease. The antibodies also exhibited patterns of reactivity with thrombin-digested FVIII similar to those of FVIII inhibitors and preferentially recognized epitopes located in the light chain of FVIII. These observations suggest that FVIII inhibitors occurring in hemophilia A and in patients with anti-FVIII autoimmune disease originate from the expansion of preexisting natural anti-FVIII clones that exhibit FVIII-neutralizing properties.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference40 articles.

1. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.;De Biasi;Thromb Haemost.,1994

2. Viral safety and inhibitor development associated with factor VIIIC ultrapurified from plasma in hemophiliacs previously unexposed to factor VIII concentrates.;Lusher;Semin Hematol.,1990

3. Recombinant FVIII for the treatment of previously untreated patients with hemophilia A.;Lusher;N Engl J Med.,1993

4. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.;Bray;Blood.,1994

5. A survey of 215 non-hemophilic patients with inhibitors to factor VIII.;Green;Thromb Haemast.,1981

Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3